文献速递脊柱脊髓外科神经肿瘤

枕颈融合术治疗颅颈交界区转移性肿瘤24年经验

Surgical outcomes of occipitocervical fusion for metastatic disease at the craniocervical junction: 24 years of experience at a tertiary cancer referral center.
PubMed 文献 · J Neurosurg Spine · 2026-02-20

该研究基于单中心前瞻性数据库,回顾2001至2024年126例枕颈融合术患者中57例转移性肿瘤病例,评估疼痛控制与并发症风险。结果显示颈部VAS评分从术前中位8降至最终随访1,MME从88.8降至53.5,总体并发症率10.5%,作者认为枕颈融合术安全有效。

要点

  • 疼痛是颅颈交界区转移瘤最常见症状,占94.6%。
  • 枕颈融合术后颈部VAS评分和MME均显著持续下降。
  • 总体并发症率10.5%,伤口愈合问题占7.0%。

核心结论

  • 枕颈融合术是处理颅颈交界区疼痛性转移瘤的安全有效选择,并发症率可接受且疼痛缓解显著。

研究设计与样本

  • 单中心回顾性队列研究,从前瞻性维护数据库纳入2001至2024年成人枕颈融合术患者,排除非转移性病例,共57例转移性肿瘤患者进行分析。

主要发现

  • 疼痛(机械性或枕神经痛)为最常见首发症状,占94.6%。
  • 肾细胞癌为最常见转移病理类型,占35.1%。
  • 颈部VAS评分从术前中位8(IQR 5-10)降至术后第1天5(IQR 3-7),6周3(IQR 0-4),3个月1(IQR 0-3),最终随访1(IQR 0-3)。
  • MME从术前中位88.8降至末次随访53.5。
  • 总体并发症率10.5%,其中伤口愈合障碍占7.0%,仅3例需翻修手术。

临床怎么用

  • 对颅颈交界区转移瘤伴顽固性颈痛或枕神经痛患者,枕颈融合术可显著缓解疼痛并减少阿片类药物用量。
  • 术后需关注伤口愈合情况,尤其老年患者并发症风险可能增高。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Metastatic disease at the craniocervical junction is rare. Typically, patients present with disabling neck pain and instability. To date, limited data exist to guide treatment strategies. In this study, the authors review 24 years of occipitocervical fusion outcomes at a tertiary cancer center with the aim of evaluating effectiveness with pain control and risk factors for complications. METHODS: Adult patients who underwent occipitocervical fusion for metastatic disease at a single institution between 2001 and 2024 were identified from a prospectively maintained database. Cases involving nonmetastatic conditions were excluded. Collected preoperative variables included patient demographics, baseline performance status, prior radiation treatments, lesion location, pathology type, and the degree of epidural spinal cord compression. The primary outcome was pain control, evaluated using the neck visual analog scale (VAS) and morphine milligram equivalents (MME) at immediate, 6-week, 3-month, and final follow-up intervals. Complications were extracted from electronic medical records and analyzed for associations with predisposing risk factors. RESULTS: A total of 126 patients underwent occipitocervical fusion, 57 of whom were treated for metastatic disease. Pain (mechanical or occipital neuralgia) was the most common presenting symptom (94.6%). Renal cell carcinoma (35.1%) was the most frequent metastatic histology. Pain outcomes showed significant improvement, with neck VAS scores decreasing from a median of 8 (IQR 5-10) preoperatively to 5 (IQR 3-7) by postoperative day 1, and further reductions to scores of 3 (IQR 0-4) at 6 weeks, 1 (IQR 0-3) at 3 months, and 1 (IQR 0-3) by the final follow-up. MME decreased from a median of 88.8 preoperatively to 53.5 at the last follow-up. The overall complication rate was 10.5%, with 7.0% attributed to wound healing disturbances. Only 3 patients required revision surgery. Age > 60 years trended toward increased complication risk (p = 0.06), although other factors were not significantly associated with complications. CONCLUSIONS: Occipitocervical fusion is a safe, effective option for managing painful metastases at the craniocervical junction, showing an acceptable complication rate and significant pain relief. This series is the largest reported on this condition.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Kimchi G, Tatsui CE, Ramirez Ferrer E, et al. Surgical outcomes of occipitocervical fusion for metastatic disease at the craniocervical junction: 24 years of experience at a tertiary cancer referral center. J Neurosurg Spine. 2026. PMID: 41719546. doi:10.3171/2025.10.SPINE25600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。